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University Health Network, Toronto, Ontario, CanadaAntineutrophil cytoplasmic antibodiesassociated vasculitis (AAV) is associated with high morbidity or
mortality, especially if not promptly diagnosed and treated. Many inroads have been made in the un-
derstanding of the pathophysiology that leads to exploration of novel therapies. Randomized controlled
trials over the last 2 decades have better delineated and expanded therapeutic options and set the stage
for an evidence-based approach. Since 2014, 4 scientiﬁc societies have systematically reviewed the
existing data and have formulated evidence-based recommendations for the management of AAV. These
recommendations cover diagnosis, remission induction and maintenance treatment, and prevention of
long-term complications. This review is a comparative analysis of the recently published recommenda-
tions of the European League Against Rheumatism/European Renal Association-European Dialysis and
Transplant Association, the British Society of Rheumatology, the Canadian Vasculitis Research Network,
and the Brazilian Society of Rheumatology, and aims to determine common ground among them and
highlights the differences among the recommendations.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A ntineutrophil cytoplasmic antibodies (ANCAs)associated vasculitides (AAV) are a heterogeneous
group of systemic necrotizing small vessel vasculitides.
More than 90% of AAV patients have circulating
ANCAs. AAV includes granulomatosis with poly-
angiitis (GPA), microscopic polyangiitis (MPA), and
eosinophilic granulomatosis with polyangiitis (EGPA).
Several landmark trials in the last 2 decades have
harmonized and optimized the treatment of AAV, which
was a frequently fatal disease before the introduction of
high-dose glucocorticoids (GCs) and cyclophosphamide
(CYC). More recent concerns have been the cumulative
toxicity of these agents and management of a chronic re-
lapsing disease course. More effective and safer induc-
tion and maintenance therapy regimens have emerged
as a result of these trials. Guidelines for managementspondence: Duvuru Geetha, 301 Mason Lord Drive, Suite
Baltimore, Maryland 21224, USA. E-mail: gduvura@jhmi.edu
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International Reports (2018) 3, 1039–1049of AAV have been published by various medical soci-
eties. This review compares 4 guidelines published in
the English language, from the: (i) British Society for
Rheumatology (BSR) and British Health Professionals
for Rheumatology (BHPR) (2014),1 updated from their
2007 guidelines2; (ii) the Canadian Vasculitis Research
Network (CanVasc) (2015)3 developed by members of
the core committee of the CanVasc research network;
(iii) the European League Against Rheumatism
(EULAR)/European Renal Association-European Dial-
ysis and Transplant Association (ERA-EDTA) (2016),4
developed by an international task force representing
EULAR, ERA, and the European Vasculitis Society
(EUVAS), updated from their 2008 guidelines5; and
(iv) the Brazilian Society of Rheumatology (SBR)
(2017), which focused only on induction therapy of
AAV (Table 1).6 There are no guidelines published
from the United States, and although the American Col-
lege of Rheumatology did not endorse the recently pub-
lished EULAR/ERA-EDTA guidelines, an American
College of Rheumatology representative contributed to1039
Table 1. Features of the compared guidelines
Society
Publication
year Stake holders Geography
BSR/BHPR 2014 Vasculitis physician experts from multiple
specialties and allied health care
professional representatives
United
Kingdom
EULAR/ERA-EDTA 2015 International task force representing EULAR,
ERA, and EUVAS, and including
physicians (internists, specialists, and
pathologists), patients, nurses
Europe
CanVasc 2016 Vasculitis physician experts from multiple
specialties
Canada
SBR 2017 Rheumatologists Brazil
BHPR, British Health Professionals in Rheumatology; BSR, British Society for Rheumatology;
CanVasc, Canadian Vasculitis research network; ERA-EDTA, European Renal Association-
European Dialysis and Transplant Association; EULAR, European League Against Rheu-
matism; EUVAS, European Vasculitis Society; SBR, Brazilian Society of Rheumatology.
REVIEW D Geetha et al.: ANCA Guideline Comparisonthese guidelines. The strength of the recommendations
made by BSR/BHPR, EULAR/ERA-EDTA, and CanVasc
is based on the categories of evidence deﬁned by
EULAR standardized operating procedures, graded
from A (highest) to D (lowest),7 and the strength of rec-
ommendations made by BSR is based on the Grading
of Recommendations Assessment, Development, and
Evaluation (GRADE) system8 and graded from A (high-
est) to D (lowest). Our aim was to determine the common
ground among the recommendations and highlight the
differences among them.
Diagnosis of AAV
CanVasc and EULAR/ERA-EDTA both recommend
obtaining tissue biopsy at diagnosis, if possible; EULAR/
ERA-EDTA also recommends biopsy at relapse. BSR/
BHPR and CanVasc speciﬁcally note that ANCA testing
should be performed with indirect immunoﬂuorescence
and enzyme-linked immunosorbent assay at diagnosis;
BSR/BHPR also recommends testing at relapse, at change
of therapy, and at every 6 months during treatment, and
annually while off treatment. Indirect immunoﬂuores-
cence alone is not sufﬁcient for diagnosis for AAV due
to the ability of autoantibodies against antigens other
than PR3 and MPO to cause a positive staining pattern.
A new international consensus statement on ANCA
testing recommends initial testing for suspected AAV
with immunoassays for PR3 ANCA and MPO ANCA
replacing the use of indirect immunoﬂuorescence.9
Disease Classiﬁcation
All 4 guidelines divide patients into those with life- or
organ-threatening disease and those without. CanVasc
speciﬁcally refers to these groups as severe versus non-
severe, which is terminology also used in the EULAR
guidelines. The distinction between the 2 categories
varies somewhat. For example, CanVasc deﬁnes severe
disease as the “presence of life- ormajor organ-threatening
manifestations, including severe and progressive kidney
involvement; severe alveolar hemorrhage; severe GI,1040cardiac, CNS, and/or eye involvements; or any other
manifestations considered severe enough to require in-
duction treatment with CYC or RTX.”3,4 In contrast,
BSR/BHPR seems to group more patients into nonsevere
disease as “those with no evidence of organ damage who
may be considered for alternative induction therapy
with MTX or MMF,” and all other patients should be
considered to have severe disease and treated with CYC
or rituximab (RTX). In addition to these categorizations,
CanVasc refers to the use of the 5-factor score for prog-
nostication of EGPA and MPA.
Remission Induction for Severe Disease
The recommendations made by the 4 guidelines are
summarized in Table 2. The protocols for the 3 landmark
trials for induction therapy are depicted in Figure 1.
Cyclophosphamide
CYC use for remission induction received a grade A
recommendation across all 4 guidelines. The preference
for i.v. CYC by BSR/BHPR is based on the results of
CYCLOPS (CyclophosphamideOral versus Pulsed)10 trial,
which demonstrated lower cumulative exposure in the
i.v. CYC arm and in earlier randomized controlled trials.11
EULAR/ERA-EDTA also favored i.v. CYC for this reason,
as well as due to a reduced risk of CYC-related bladder
complications. SBR and CanVasc recommend either oral
or i.v. pulsed CYC. CanVasc also notes the potential lower
rate of relapse on longer term follow-up with oral CYC.
The standard dosing for oral CYC is 2 mg/kg per day
(maximum200mg/d), and dosing for i.v. CYC is 15mg/kg
(maximum 1.2 g/pulse), given 3 times 2 weeks apart, and
then once every 3 weeks for 3 to 6 months (CYCLOPS).
Rituximab
RTX is generally recommended as an alternative to CYC
for remission induction of AAV. BSR/BHPR (grade B
recommendation) and EULAR/ERA-EDTA (grade A
recommendation) recommend it as a ﬁrst-line alterna-
tive without particular restrictions, although EULAR
notes that the data remain weakest among patients with
EGPA. SBR also recommends it as an alternative,
highlighting a particular role in patients in whom CYC
is contraindicated or not preferred due to fertility or
other concerns, or in those with relapsing disease.
CanVasc is the most restrictive, specifying RTX as a
ﬁrst-line remission induction in patients with severe
GPA/MPA disease in whom CYC is contraindicated
and/or not preferred. None of the guidelines recom-
mend against RTX as ﬁrst-line induction treatment. The
main drawbacks cited are access and/or cost barriers.
Glucocorticoids
GCs are an ubiquitous part of front-line induction
therapy. Patients with severe disease may be adminis-
tered i.v. pulse methylprednisolone initially. AllKidney International Reports (2018) 3, 1039–1049
Table 2. Induction therapy in severe disease and refractory disease
Category Common view Differences
Severe disease CYC CYC with high-dose steroids for ﬁrst-line induction is
universally recommended.
GC þ CYC therapy should be continued for 36 mo, then
switched to a less toxic maintenance therapy when
remission is achieved. Dosing adjustments should be
made for age and renal function (BSR, CanVasc, SBR)
Formulation
SBR and CanVasc: Either oral or i.v. pulsed CYC.
BSR and EULAR: Favor i.v. pulsed CYC
Dosing
BSR, SBR: Standard 15 mg/kg, max 1.2 g (SBR)
1.5 g (BSR) per pulse, ﬁrst 3 pulses at 2-wk intervals, then every 3 wks for total of
36 mos
EULAR: not speciﬁed, but refers to CYCLOPS trial, which is same as the preceding
RTX All 4 guidelines recommend RTX with high-dose steroids for
ﬁrst-line induction in patients in whom CYC is
contraindicated or not preferred
First line RTX:
BSR and EULAR: recommend RTX ﬁrst-line in general for all AAV patients; EULAR
notes that the data are weakest among patients with EGPA.
SBR: recommends RTX as an alternative in patients in whom CYC is contraindicated
or not preferred
CanVasc: recommends GC þ RTX as ﬁrst-line remission induction in patients with
severe GPA or MPA in whom CYC is contraindicated or not preferred
Dosing:
SBR: rituximab should be given at 375 mg/m2 weekly for 4 wks, or in 2 infusions
2 wks apart at a dose of 1 g.
BSR and CanVasc: recommend 375 mg/m2 weekly for 4 wks
GC dosing Every patient should receive systemic GCs. In severe disease,
patient may be started ﬁrst on i.v. pulse methylprednisolone
Oral GC dosing and schedule:
BSR: start oral prednisolone at 1.0 mg/kg per day (max, 60 mg/d), tapered to
15 mg per day at 12 wks.
SBR: start prednisone at 0.5-1.0 mg/kg per day (max, 80 mg/d) for 14 wks,
taper by 10 mg for 24 wks until 20 mg/d, then reduce by 2.55.0 mg every 2
4 wks until full withdrawal.
CanVasc: start prednisone equivalent at 1.0 mg/kg per day (max, 6080
mg/d) for 1 mo, then gradually tapered
EULAR: 1.0 mg/kg per day (max, 80 mg/d)
i.v. pulse methylprednisolone dosing:
BSR: 200500 mg/d before or with ﬁrst 2 doses of CYC
CanVasc: 5001000 mg/d for 13 days
SBR: 5001000 mg/d or 15 mg/kg per day for 13 days
EULAR: not speciﬁed
i.v. Ig SBR: patients with infection and persistent disease, with disease refractory to GC þ
CYC, or contraindications to CYC or RTX should be given i.v. Ig
CanVasc: there is insufﬁcient evidence for any speciﬁc recommendation of i.v. Ig,
but it could have a role in certain subgroups such as adjunct in refractory
disease, pregnant women in whom other immunosuppressants are
contraindicated, and those with current severe infection or recurrent severe
infections
EULAR: i.v. Ig can be given as an adjunct therapy in the refractory setting.
Other agents Etanercept should not be used to treat AAV; other TNF-a
inhibitors have limited evidence (BSR, CanVasc, SBR)
SBR: recommends against azathioprine in the remission induction setting
BSR, CanVasc: Possible experimental options for refractory disease include
mepolizumab for patients with EGPA, alemtuzumab (anti-CD52).
BSR: other experimental options include gusperimus and leﬂunomide.
Refractory disease All refractory patients should be referred to a vasculitis center
(BSR, CanVasc, EULAR)
Patients who received CYC:
BSR and EULAR: all refractory patients with severe disease who have failed CYC
should receive RTX.
CanVasc: Severe GPA/MPA patients in whom CYC failed should receive RTX.
Patients who received RTX:
EULAR: refractory patients who received RTX should now receive CYC.
These patients can be considered for more experimental treatments at a vasculitis
referral center (BSR, CanVasc). Other strategies include adjunct i.v. Ig and
switching from pulsed to oral CYC (when RTX is unavailable/cannot be
administered). (EULAR).
BSR, British Society for Rheumatology; CanVasc, Canadian Vasculitis research network; CYC, cyclophosphamide; EULAR, European League Against Rheumatism; GC, glucocorticoids;
GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; RTX, rituximab; SBR, Brazilian Society of Rheumatology.
D Geetha et al.: ANCA Guideline Comparison REVIEWguidelines acknowledge that the data on the beneﬁts of
i.v. methylprednisolone are limited. BSR/BHPR recom-
mends 250 to 500 mg pulse before or with the ﬁrst 2 CYC
infusions. CanVasc and SBR recommend using i.v.
methylprednisone 500 to 1000mg/d for 3 days preceding
oral prednisone in life-threatening and/or organ-
threatening AAV. CanVasc gives a grade B recommen-
dation, and SBR gives a grade C recommendation for use
of i.v. methylprednisone. EULAR does not provide
speciﬁc recommendations on the use of i.v.Kidney International Reports (2018) 3, 1039–1049methylprednisolone. Patients should be started on oral
prednisone equivalent to 0.5 to 1 mg/kg per day with a
maximum of 60 to 80 mg/d, and then tapered. The
CanVasc discusses prednisone-tapering protocols in the
RAVE (rituximab for ANCA-associated vasculitis)12 and
RITUXVAS (rituximab versus cyclophosphamide in
ANCA-associated vasculitis)13 trials in the supplement13
and recommends that a prednisone dose of 1 mg/kg per
day be continued for a maximum of 1 month, with a
gradual taper and dose adjustment based on the clinical1041
CYCLOPS Trial
*Oral CYC 2 mg/kg 
daily + GC
*i.v. CYC 15 mg/kg 
every 2–3 weeks + GC
Connue CYC unl 
remission + 3 months
Switch to remission 
maintenance with AZA 
2 mg/kg daily
Study end period: 18 months
GC dosing (PO prednisone): 
-Start: 1 mg/kg/d
-Tapered to 10 mg by month 5
-Tapered to 7.5 mg by month 12
-Tapered to 5 mg by month 15
RAVE Trial
RTX 375 mg/m2
weekly x 4 doses + GC
†Oral CYC 2 mg/kg  
daily + GC
No maintenance Switch to AZA 2 mg/kg daily by month 4
i      il  
–6
Study end period: 18 months
GC dosing:
-Methylprednisolone 1 g i.v. daily x 3 doses followed by oral 
prednisone 
-Start: PO prednisone 1 mg/kg daily 
-Week 4: PO prednisone 40 mg 
-Tapered every 2 weeks to (30, 20, 15, 10, 7.5, 5, 2.5, oﬀ)
RITUXVAS Trial
-RTX 375 mg/m2 weekly x 4 
doses
-*i.v. CYC 15 mg/kg at week 
0 and week 4
-Methylprednisolone 1 g i.v. 
x 1 dose followed oral 
prednisone
-*i.v. CYC 15 mg/kg every 2 
weeks x 3 doses, then 
every 3 weeks x 7 doses 
(minimum 3 months, 
maximum 6 months)
-Methylprednisolone 1 g i.v. 
x 1 dose followed oral 
prednisone
No maintenance 
Remission maintenance with 
AZA 2 mg/kg daily aer 3-6 
months of CYC 
Study end period: 24 months
GC dosing (PO prednisone) following the 1 g i.v.
Methylprednisolone dose: 
-Start: 1 mg/kg/d
-Tapered to 12.5 mg by month 3
-Month 4: 10 mg
-Month 5: 7.5 mg
-Month 6: 5 mg
-Month 18 to 24: reduce from 5 mg to 2.5 mg 
Figure 1. Treatment Protocols in CYCLOPS, RAVE, and RITUXVAS Trials. *CYC dose adjusted for renal function and age. †CYC dose adjusted for
renal function. AZA, azathioprine; CYC, cyclophosphamide; GC, glucocorticoids; PO, oral; RITUXVAS, rituximab versus cyclophosphamide in
ANCA-associated vasculitis; RTX, rituximab.
REVIEW D Geetha et al.: ANCA Guideline Comparisoncourse of the patient (recommendation C). The EULAR/
ERA-EDTA recommends a target dose of 10 to 15 mg of
prednisone daily after 12 weeks of treatment. BSR rec-
ommends rapid tapering for prednisone 15 mg/d at 121042weeks. SBR recommends a slow prednisone-tapering
regimen, with an initial daily dose of 0.5 to 1.0 mg/kg
per day (maximum 80 mg/d) for 1 to 4 weeks, followed
by tapering 10 mg every 2 to 4 weeks until 20 mg/d.Kidney International Reports (2018) 3, 1039–1049
Table 3. Recommendations for use of plasma exchange in induction therapy of antineutrophil cytoplasmic antibodiesassociated vasculitides
Disease manifestation Common view Differences
Plasmapheresis Rapidly progressive
glomerulonephritis
CanVasc states there is insufﬁcient evidence to recommend
plasmapheresis for patients with severe renal or pulmonary
involvement, but it may be a reasonable adjuvant if a patient is
refractory to high dose GC þ CYC/RTX.
BSR, SBR, and EULAR recommend consideration of plasma
exchange for RPGN with serum Cr greater than w500
mmol/l (5.7 mg/dl).
Plasmapheresis Diffuse alveolar hemorrhage There is insufﬁcient evidence, but may be considered/possibly of
beneﬁt as an adjuvant when patients are in this setting and
refractory to standard GC þ CYC/RTX (all 4 guidelines)
BSR, British Society for Rheumatology; CanVasc, Canadian Vasculitis research network; CYC, cyclophosphamide; EULAR, European League Against Rheumatism; GC, glucocorticoids;
GPA, granulomatosis with polyangiitis; RTX, rituximab; SBR, Brazilian Society of Rheumatology.
D Geetha et al.: ANCA Guideline Comparison REVIEWAfterward, they suggest that dose reduction should be
2.5 to 5.0 mg every 2 to 4 weeks until complete with-
drawal. The initial starting dose of prednisone received a
grade B recommendation across all guidelines, whereas
the tapering regimen received a grade C from CanVasc
and BSR/BHPR and grade D from SBR.
Regarding the duration of GC therapy, there are dif-
ferences across the guidelines. CanVasc states low-dose
GCs should be part of the initial maintenance therapy
and notes that there is not enough evidence yet to sup-
port the optimal duration of low-dose GCs. EULAR does
not provide recommendations on GC duration. SBR
recommends that the duration of GC therapy should be
at least 6 months, and, in some instances, it may be up to
1 or 2 years. Longer duration of GCs may be necessary in
relapsing patients (recommendation A by BSR/BHPR
and recommendation B by BSR).Recommendations Regarding Use of Plasma
Exchange
CanVasc states that plasma exchangemay be a reasonable
adjuvant therapy for patients who deteriorate due to
active vasculitis despite ongoing remission induction
therapy with high-dose GCs plus CYC or RTX. However,
there is insufﬁcient evidence to recommend plasma
exchange as ﬁrst-line therapy in any patient with
AAV (grade D recommendation). BSR/BHPR and
EULAR/ERA-EDTA recommend that plasma exchange
should be used along with CYC and GCs in patients
presenting with severe renal failure with serum creati-
nine >500 mmol/l (grade B recommendation) or
life-threatening manifestations, such as pulmonary
hemorrhage (grade C recommendation). SBR recom-
mends use of plasma exchange along with GCs and CYC
in patients with serum creatinine >5.8 mg/dl (grade A
recommendation) and notes there is insufﬁcient evi-
dence to support plasma exchange to treat AAV patients
who present with alveolar hemorrhage (Table 3).
CanVasc and EULAR/ERA-EDTA state that the
ongoing PEXIVAS (Plasma Exchange and Glucocorti-
coids for Treatment of Anti-Neutrophil CytoplasmKidney International Reports (2018) 3, 1039–1049Antibody Associated Vasculitis) trial may provide more
deﬁnitive answers regarding efﬁcacy and safety of
plasma exchange in AAV.
Remission Induction for Nonsevere Disease
Methotrexate and Mycophenolate Mofetil
Generally, patients with nonsevere and nonorgan-
threatening disease are recommended a milder regimen
than CYC or RTX. BSR/BHPR and EULAR guidelines
recommend systemic GCs with either methotrexate
(MTX) or mycophenolate mofetil (MMF) (grade B
recommendation for MTX and grade C recommendation
for MMF), whereas CanVasc and SBR only recommend
GCs with MTX (grade A recommendation). The EULAR/
ERA-EDTA guidelines emphasize that nonsevere and
nonorgan-threatening had different meanings and listed
organ-speciﬁc scenarios when MTX use was inappro-
priate. All guidelines recommend dose adjustment of
MTX for renal function. EULAR/ERA-EDTA states that
MTX can be used in the absence of renal involvement and
BSR/BHPR states thatMTX should not be used in patients
with moderate or severe renal involvement (grade B
recommendation). CanVasc recommends dose adjustment
when the glomerular ﬁltration rate (GFR) is between 50
and 80 ml/min per square meter, to consider alternative
therapy when GFR is <50 ml/min per square meter, and
to avoid use when GFR is <10 ml/min per square meter.
SBR recommends that the MTX dose should be decreased
by 50% in patients with GFRs of 10 and 50 ml/min per
square meter and to avoid use when GFR is <10 ml/min
per square meter (grade D recommendation).
Patients With Nonsevere EGPA or MPA Without
Renal Involvement
CanVasc states that it is acceptable to treat patients
with nonsevere EGPA or MPA without renal involve-
ment with GCs alone. It cites 2 studies from the French
Vasculitis Study Group, which showed that GCs alone
induced remission in a signiﬁcant portion of patients—
93% of patients with EGPA14 and 79% of patients with
MPA or polyarteritis nodosa15—although there were
with signiﬁcant relapse rates. In these studies, patients1043
Table 4. Maintenance therapy and management of relapse
Category Common view Differences
Maintenance Patients with severe AAV in remission after GC þ CYC should receive
maintenance therapy with GC þ an immunosuppressant drug, among
which AZA and MTX are most universally recommended.
Population who should receive maintenance therapy:
BSR, CanVasc: severe AAV in remission after GC þ CYC
CanVasc: there is no clear evidence/consensus to guide decisions for mainteannce after RTX
EULAR: not speciﬁed
Agent:
BSR: AZA or MTX in combination with GC. LEF or MMF may be alternatives. RTX is also an option.
CanVasc: AZA or MTX, initially in combination with low-dose GC. LEF and MMF are second-
line alternatives. RTX is also an option particularly in PR3-ANCA-positive GPA. TMP/SMX can
be considered as adjuvant maintenance therapy after normal maintenance with an
immunosuppressant in patients with GPA.
EULAR: Patients with GPA/MPA should receive low-dose GC and AZA, RTX, MTX, or MMF (greatest
consensus for AZA); those with EGPA should receive AZA. LEF is a second-line option. TMP/
SMX can be considered as adjuvant therapy but is not recommended alone.
Duration of immunosuppressant agent in general:
BSR, EULAR: 24 mos after duration.
CanVasc: 18 mos, but no clear evidence.
Duration of immunosuppressant agent for PR3-ANCAþ patients:
BSR: up to 5 yrs
EULAR: evidence still pending, but 36 mos
Duration of GCs:
BSR: patients in remission after 1 yr can begin to taper GCs. After GCs are withdrawn, the other
immunosuppressive agent can be tapered after 6 mos.
- CanVasc: no clear evidence for GC duration
Relapse Patients who have a severe relapse should receive GC þ CYC or RTX
(BSR, CanVasc, EULAR).
Nonsevere relapse may be managed with increasing the dosage of GC in
addition to optimizing current immunosuppressant agent
(BSR, CanVasc, EULAR).
Severe relapse
BSR: Severe relapse should be treated with GC þ CYC or RTX. If the patient is trying a second
round of GC þ CYC, the dose of GC should be increased; addition of i.v. methylprednisolone
and PLEX can be considered. Also, drivers for relapse should be identiﬁed.
CanVasc: Patients who already tried GC þ CYC should receive RTX.
EULAR: In general, due to the cumulative toxicity of CYC, RTX is recommended over CYC in
relapsing disease.
AAV, antineutrophil cytoplasmic antibodies (ANCA)associated vasculitides; AZA, azathioprine; BSR, British Society for Rheumatology; CanVasc, Canadian Vasculitis research network;
CYC, cyclophosphamide; EGPA, eosinophilic granulomatosis with polyangiitis; EULAR, European League Against Rheumatism; GC, glucocorticoids; GPA, granulomatosis with polyangiitis;
LEF, leﬂunomide; MMF, mycophenolate mofetil; MPA, microscopic polyangiitis; MTX, methotrexate; RTX, rituximab; SBR, Brazilian Society of Rheumatology; TMP/SMX, trimethoprim/
sulfamethoxazole.
REVIEW D Geetha et al.: ANCA Guideline Comparisonin whom GCs failed or patients who relapsed would
then receive azathioprine (AZA) or CYC, both of which
were effective in that setting.14,15 None of the other
guidelines advocate use of GCs alone.
Maintenance Treatment
Table 4 provides an overview of the common view and
differences across these guidelines.
Patient Population
For patients with severe AAV who are in remission
after successful induction therapy with GCs þ CYC,
maintenance therapy is universally recommended
across all guidelines, except for SBR, which focuses on
induction therapy only. CanVasc is the only guideline
that speciﬁcally discusses patients who receive GCs þ
RTX as induction therapy, stating that there is no
adequate evidence yet for recommending any speciﬁc
approach.
Maintenance Therapy Selection Among Conventional
Immunosuppressants
Remission is deﬁned by EULAR/EUVAS as the complete
absence of clinical disease activity, including vasculitis
and granulomatous manifestations, whether patients are
receiving immunosuppressive therapy or not. EULAR/
ERA-EDTA recommends use of low-dose GCs in com-
bination with azathioprine, RTX, MTX, or MMF (in this1044order of preference) for remission maintenance. The use
of these agents for remission maintenance received a
grade A recommendation for GPA and MPA and a grade
C recommendation for EGPA. Leﬂunomide was recom-
mended as a second-line treatment due to adverse
effects mentioned by EULAR/ERA-EDTA.
BSR/BHPR and CanVasc recommend use of low-dose
GCs combined with AZA or MTX as ﬁrst-line therapy
for remission maintenance (grade A recommendation)
and use of MMF (recommendation C by BSR/BHPR and
recommendation B by CanVasc) or leﬂunomide (grade B
recommendation for both) as alternatives when patients
are intolerant or refractory to AZA and MTX, or in
whom these agents are contraindicated. RTX is also
recommended as an alternative maintenance agent by
BSR/BHPR with a grade C recommendation. The Can-
Vasc guideline has clariﬁed that there is no deﬁnitive
evidence to guide decisions for maintenance therapy
after remission induction with RTX. They recommend
use of RTX as an alternative to AZA for remission
maintenance therapy, especially in PR3 ANCA-positive
patients (grade A recommendation).
Duration of Maintenance Therapy
BSR/BHPR and EULAR recommend at least 24 months of
immunosuppressive therapy following successful
remission induction (recommendation B by BSR/BHPRKidney International Reports (2018) 3, 1039–1049
D Geetha et al.: ANCA Guideline Comparison REVIEWand recommendation D by EULAR), whereas CanVasc
recommends at least 18 months of maintenance therapy,
after which treatment is discontinued at the discretion of
the physician according to the individual characteristics,
treatment tolerance, and understanding of subsequent
relapse risk of the patients (recommendation C).
However, patients with PR3 ANCA disease are more
likely to relapse and are generally recommended a longer
course ofmaintenance therapy (EULAR, 36months; BSR/
BHPR, up to 5 years). BSR/BHPR is the only guideline
that provides guidance on duration of RTX for mainte-
nance therapy: every 4 to 6 months for 2 years (recom-
mendation B). CanVasc is the only guideline to note that
there is insufﬁcient evidence to guide optimal GC dura-
tion. CanVasc also addresses the use of trimethoprim/
sulfamethoxazole (TMP/SMX) as an adjuvant to immu-
nosuppressants or after cessation of immunosuppressive
therapy in GPA patients (recommendation C).
Withdrawal of Treatment
BSR/BHPR recommends that patients in continual
remission for at least 1 year on maintenance therapy
should be considered for tapering of GC treatment. After
GC withdrawal, other immunosuppressive therapy may
be tapered after 6 months (recommendation D). No rec-
ommendations regarding withdrawal of immunosup-
pressive treatment are made by the EULAR, CanVasc,
and SBR guidelines.
Treatment of Refractory Disease
BSR/BHPR, EULAR, and CanVasc provide recommen-
dations or statements for treatment of refractory disease,
whereas SBR does not speciﬁcally address refractory
disease. All guidelines underscore that refractory
patients should be managed in collaboration with or at a
vasculitis referral center. The deﬁnition of refractory
disease differs across the guidelines. EULAR deﬁnes
refractory disease as unchanged or increased disease
activity after 4 weeks of an appropriate dose of CYC
with GCs; lack of response, deﬁned as #50% reduction
in disease activity score and/or lack of improvement in
at least 1 major item after 4 to 6 weeks of treatment; or
chronic persistent disease, deﬁned as the presence of at
least 1 major or 3 minor items on the Birmingham
Vasculitis Activity Score (BVAS) list despite 8 weeks of
treatment. CanVasc deﬁnes refractory disease as un-
changed or worsening disease despite 6 weeks of
appropriate remission induction therapy or the presence
of persistent disease activity after 3 months of appro-
priate remission induction therapy. BSR/BHPR deﬁnes
refractory disease as progressive disease that is unre-
sponsive to current therapy and recommends that
drivers for refractory disease should be sought, and
clinicians should consider revision of the clinicalKidney International Reports (2018) 3, 1039–1049diagnosis. EULAR and CanVasc recommend that it is
important to ensure that the diagnosis is correct, alter-
nate infectious and/or neoplastic diagnoses have been
excluded, and that the treatment, including drug
choice, dosage and duration, was appropriate in all cases
of apparent refractory disease.
Rituximab and Cyclophosphamide
Patients with severe AAV in whom remission induction
with ﬁrst-line CYCþ GCs has failed should receive RTX
(recommendation A by BSR/BHPR and recommenda-
tion C by EULAR and CanVasc). CanVasc speciﬁes this
for patients with severe GPA and MPA, noting that the
management of EGPA patients is less clear-cut. Because
more patients are receiving RTX as a ﬁrst-line therapy,
EULAR also notes that those who received ﬁrst-line
RTX but in whom it failed should receive CYC
(recommendation C).
Other Treatments in the Refractory Setting
A variety of other experimental treatments have been
used in the setting of refractory disease. I.v. Ig is rec-
ommended as an adjunct therapy in refractory AAV by
BSR/BHPR, EULAR, and CanVasc (grade C recommen-
dation). BSR/BHPR and CanVasc refer to the use of
alemtuzumab for refractory disease (grade D recom-
mendation). Other agents suggested for use in re-
fractory AAV by BSR/BHPR include gusperimus and
leﬂunomide. BSR/BHPR and CanVasc recommend
against use of etanercept, an antitumor necrosis factor
medication, due to increased risk of infection and ma-
lignancy (grade A recommendation). CanVasc and BSR/
BHPR refer to use of mepolizumab for refractory EGPA.
Treatment of Disease Relapse
Severe Relapse
The treatment of major and/or severe disease relapse is
similar to initial induction treatment and generally
consists of high-dose GCs þ RTX or CYC (grade A
recommendation by BSR/BHPR, EULAR/ERA-EDTA,
and CanVasc), with RTX being the more recom-
mended agent. In the RAVE study, among the sub-
group of patients who relapsed, RTX was superior to
CYC at 6 and 12 months, but the difference was not
signiﬁcant at 18 months. CanVasc recommends use of
RTX preferentially for patients who received CYC for
initial disease remission induction or a previous disease
ﬂare. EULAR/ERA-EDTA favored use of RTX for re-
lapsing disease because of the toxicity associated with
cumulative CYC use. BSR/BHPR recommends addition
of i.v. methylprednisolone or plasma exchange for se-
vere and/or major relapses (grade C recommendation),
and CanVasc notes that there is insufﬁcient evidence to
support a recommendation to use plasma exchange as
ﬁrst-line therapy, but suggests that plasma exchange1045
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tients who deteriorate clinically despite ongoing
treatment with GCs plus CYC or RTX (grade D recom-
mendation). For patients who do receive a second
course of CYC, BSR/BHPR recommends that the GC
dose be increased. CYC may also be appropriate for
patients who received RTX as ﬁrst-line therapy or who
cannot receive RTX because of contraindications.
Nonsevere Relapse
Patients with nonsevere relapse may be managed by
optimizing the immunosuppressive regimen and/or
increasing the GC dose. BSR/BHPR, EULAR/ERA-EDTA,
and CanVasc recommend treatment of nonsevere re-
lapses with an increase in the GC dose in addition to
intensiﬁcation or modiﬁcation of the remission mainte-
nance regimen (grade C recommendation) without
making speciﬁc recommendations on the choice or
change of immunosuppressant and duration of therapy
after a nonsevere relapse.
Management of Speciﬁc Disease Manifestations
Ear, Nose, and Throat Disease and Subglottic
Stenosis
Patients with GPA and ear, nose, and throat involve-
ment may require additional local therapy for ear, nose,
and throat disease. The treatment of topical mupirocin
may be used in patients who have Staphylococcus
aureus according to the BSR/BHPR and EULAR/ERA-
EDTA guidelines. BSR speciﬁcally recommends per-
forming a bacterial swab at baseline and at every 6 to
12 months to detect S. aureus colonization, which is
associated with an increased risk of relapse. However,
CanVasc concludes that this is of limited beneﬁt and
has not been shown to lower the risk of relapse or
progression from a limited ear, nose, and throat to a
more systemic form of the disease in GPA patients. SBR
discusses subglottic stenosis in particular, recom-
mending that patients with concurrent systemic disease
receive systemic therapy, whereas those with sub-
glottic stenosis should only receive local therapy, such
as ﬁrst-line mechanical dilation with long-acting GC
injection (grade C recommendation).
Prophylaxis Against Pneumocystis jirovecci
All 4 guidelines recommend prophylaxis for Pneumo-
cystis jirovecci in AAV patients receiving induction
therapy with CYC or RTX. SBR speciﬁes that all patients
with a total lymphocyte count of<300 cells/mm3 should
receive prophylaxis, regardless of immunosuppression
therapy. The recommended ﬁrst-line prophylaxis by all
guidelines in the absence of allergy is TMP/SMX at a
dose of 400/80 mg daily or 800/160 mg 3 times a week.
Dose adjustment for renal impairment is recommended
in the SBR guideline. CanVasc recommends continuingP1046jirovecci prophylaxis 3 months after stopping CYC.
CanVasc notes that the optimal duration of P jirovecci
prophylaxis after the RTX-based induction regimen is
unknown. CanVasc highlights that there is no consensus
on P jirovecci prophylaxis for AAV patients who receive
monotherapywith high-doseGCs. Except for patients on
MTX (with which TMP/SMX interacts), BSR and Can-
Vasc specify that TMP/SMX is generally safe at the
prophylaxis dose. BSR recommends that if using TMP/
SMX in patients who are onMTX, that is not be given on
the same day as MTX. SBR recommends that these pa-
tients receive inhaled pentamidine instead of TMP/SMX.
Alternative therapy varies slightly among the
guidelines. BSR/BHPR recommends either inhaled
pentamidine or dapsone. CanVasc and EULAR/ERA-
EDTA both recommend dapsone or atovaquone more
than inhaled pentamidine. CanVasc cites a 2008 study
that found aerosolized pentamidine to be less effective
than TMP/SMX at preventing P jerovecci16; EULAR
states that inhaled pentamidine is less cost-effective
and not routinely indicated. SBR recommends inhaled
pentamidine only.
Monitoring and Management of Treatment Side
Effects
Patients Receiving CYC
BSR/BHPR, CanVasc, and EULAR/ERA-EDTA discuss a
number of precautions for patients receiving CYC.
During CYC treatment, patients should undergo routine
monitoring of blood counts, particularly for leukopenia
and/or neutropenia. Patients should also be monitored
for renal and liver function with possible therapy ad-
justments as needed. Patients who receive i.v. CYC
should receive adequate hydration and antiemetics
during administration. BSR and EULAR/ERA-EDTA
notes that the use of Mesna may be considered for
possible beneﬁt in preventing cystitis in patients who
receive pulse i.v. and oral CYC. Patients who have been
exposed to CYC and who have persistent hematuria
should be referred for consideration of cystoscopy. BSR
and CanVasc also speciﬁcally recommend that patients
exposed to CYC receive lifelong urinalysis every 3 to 6
months to monitor for hematuria. With respect to
fertility, all 4 guidelines discuss the impact on patients of
reproductive age, noting the importance of counseling
and consideration of substituting RTX when appro-
priate. BSR more speciﬁcally recommends offering pa-
tients fertility preservation, such as sperm and oocyte
cryopreservation, hormonal ovarian stimulation, use of
gonadotropin-releasing hormone analogues during CYC
therapy, and so on.
Patients Receiving RTX
BSR/BHPR, EULAR/ERA-EDTA, and SBR discuss the
importance of measuring serum Ig levels at baselineKidney International Reports (2018) 3, 1039–1049
D Geetha et al.: ANCA Guideline Comparison REVIEWand before each course of RTX, with possible therapy
modiﬁcation or replacement therapy as needed. BSR/
BHPR and SBR speciﬁcally make vaccination recom-
mendations, including hepatitis B, pneumococcal, and
annual inﬂuenza vaccinations. BSR/BHPR recommends
that the vaccine be administered at least 2 weeks before
therapy but ideally at 4 to 6 weeks, whereas SBR rec-
ommends 3 weeks. SBR also speciﬁes measurement of
HIV, hepatitis B virus (HBV), and syphilis serology
before infusion, and possible concurrent antiviral
treatment for HBV/HIV patients in collaboration with
an infectious disease specialist.
Other Adverse Effect Concerns Associated With
Immunosuppression
BSR/BHPR and CanVasc both specify that patients with
AAV should have periodic systematic assessment of
osteoporosis risk factors with appropriate prophylaxis
and treatment. BSR/BHPR lists several other concerns,
such as screenings (and appropriate management) for
oral candidiasis, cervical invasive neoplasia and/or
human papillomavirus among female patients, tubercu-
losis, thromboembolic risk, and varicella zoster titers.
Special Populations
Pregnancy
Pregnancy is only speciﬁcally discussed in the CanVasc
guidelines, which recommends no pregnancy earlier
than 6 months after remission and referral to an
obstetrician specializing in high-risk pregnancies.
Pediatric Population
Pediatric patients are also only speciﬁcally discussed in
the CanVasc guidelines. Referral is recommended to a
pediatric specialist at an academic center, with man-
agement under or in collaboration with a vasculitis
specialist. At diagnosis, pediatric patients should be
classiﬁed by severity based on EULAR/Paediatric
Rheumatology International Trials Organisation/
Paediatric Rheumatology European Society criteria to
tailor treatment.17 Otherwise, they can be treated like
adults with appropriate dosing adjustments for age
and/or size.
General Care Approach and Follow-up
Setting of Care
Most of the guidelines (BSR/BHPR, CanVasc, and
EULAR) recommend that all patients with AAV be
referred to or treated in collaboration with a vasculitis
referral center and/or center of excellence, especially if
the disease is challenging and in the refractory and/or
relapse settings. BSR/BHPR notes that there should be
collaboration with a primary care physician to improve
monitoring and compliance, although the actual
assessment of vasculitic disease should still be by
specialists.Kidney International Reports (2018) 3, 1039–1049Disease Assessment Tools
BSR/BHPR recommends use of validated tools to assess
disease activity and extent of disease. BVAS version 318
was recommended for disease activity assessment, and
the Vasculitis Damage Index (VDI)19 was recommended
for determining the extent of the irreversible damage
resulting from both disease and treatment-related
damage. It is also recommended that BVAS and VDI
be used by staff trained in their use. Quality of life
assessment using SF-36 is recommended by BSR/BHPR.
Although these tools are used in clinical trials, BSR/
BHPR recommends using these tools in routine practice
to facilitate good quality of care and enable auditing of
disease outcomes. EULAR, CanVasc, and SBR do not
mention use of these disease activity tools.
Frequency of Disease Assessment
BSR/BHPR recommends disease assessment should
occur monthly during remission induction, every 3
months during initial remission maintenance treatment,
thereafter every 6 months, and then annually. CanVasc
recommends patients receiving remission induction
and maintenance therapy to have regular clinical
assessment to monitor their treatment response, disease
course, and adverse events. Monitoring frequency
suggested by CanVasc is monthly during remission
induction and every 3 months for 2 years while on
remission maintenance therapy, and annually there-
after. No recommendation on frequency of disease
assessment is made by EULAR or SBR.
Cardiovascular Risk Factors
Most of the guidelines (BSR/BHPR, CanVasc, EULAR)
specify that patients with AAV should receive periodic
systematic assessment of cardiovascular risk factors.
Patient-Centered Care
Patients with AAV should receive clear education on
their disease, management options, side effects, and
prognosis. They should be assessed for social
and biological impacts, and provided with therapies
and support (BSR, EULAR). BSR delves further, rec-
ommending using validated tools to assess not only
disease activity and/or extent, but also quality of life. It
recommends annual holistic reviews of these areas with
appropriate resulting action plans, with a speciﬁc
emphasis on optimizing the patient’s chance of main-
taining employment. It also discusses complementary
and/or alternative medicine, which, although not sub-
stantiated by evidence, should be kept accessible to
patients for symptomatic management.
Conclusions
This review reveals numerous areas of consensus in the
management of AAV, but also highlights fundamental
differences among the 4 compared guidelines. These1047
REVIEW D Geetha et al.: ANCA Guideline Comparisondistinctions exist largely due to a lack of controlled trials
in the topic in question, with differing expert opinions,
despite an increase in clinical trial activity over the past 2
decades. Some of the differences noted across the guide-
lines may be attributed to different perspectives for the
access and/or cost of treatments. Great strides have been
made in reﬁning induction therapy for AAV. In this
context, we must acknowledge that the GC regimen,
which is 1 of the 2 central pillars of induction therapy, is
associatedwithmajor toxicity, is not evidence-based, and
varies across the guidelines. There are other areas where
evidence is lacking, including management of pediatric
vasculitis and treatment of severe AAV because these
patients are largely excluded from clinical trials, identi-
fying AAV phenotypes where treatment is futile, AAV
management in the setting of infection, and management
of EGPA. Because the use of RTX for remission induction
and maintenance therapy is expanding, more guidance is
needed to assess infection risk and recommend infection
prophylaxis. In addition, the most important outcome
is follow-up beyond 10 years, including quality of life
and risk of end-stage renal disease and cardiovascular
mortality; the data are scarce in this regard.
Guidelines are necessarily based on published evi-
dence and are therefore retrospective in nature,
covering evidence accrued over a long period of time.
This is a particular problem for a disease whose man-
agement is subject to a rapid pace of change. Further-
more, for example, the initial design of the trial and the
drug regimen that occurred years before the published
result determines much of the detail of the recommen-
dation. There is then a potential conﬂict between the
opinions of currently active, “expert” physicians, and
the more historic evidence. This balance is hard to
explore among recommendation statements but may
account for some of the variance; it also supports the
routine recommendation that patients should be
managed in experienced centers, and that physicians
managing AAV cannot simply rely on a set of published
guidelines. Finally, we should be aware that each patient
is unique, and although these guidelines can assist
physicians in decision making, they do not replace the
insight of the experienced physician in crafting a ther-
apeutic regimen tailored to the individual patient.DISCLOSURE
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